Evotec Subsidiary Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV, Financial Terms Undisclosed
Portfolio Pulse from Benzinga Newsdesk
Evotec SE's subsidiary, Just - Evotec Biologics, expands its development and manufacturing agreement with ABL for HIV antibodies, funded by Federal funds under an IDIQ contract from NIAID, NIH, DHHS. The expansion includes developing a third bNAb and large-scale cGMP manufacturing for a Phase I clinical study.
February 07, 2024 | 7:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evotec SE's subsidiary expands its agreement with ABL for the development and manufacturing of HIV antibodies, indicating potential growth in its biologics sector.
The expansion of the agreement with ABL underlines Evotec's commitment to advancing HIV treatment, potentially enhancing its reputation and financial performance in the biologics sector. The involvement of Federal funds through an IDIQ contract suggests a strong backing and a positive outlook for the project's success, likely leading to increased investor confidence in Evotec's capabilities and future prospects.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90